BIO Priorities: Negotiating Medicare Reimbursement, Reducing Drug Development Times
This article was originally published in The Pink Sheet Daily
"Eternal vigilance" is necessary to ensure reimbursement is not adversely affected by implementation of Medicare drug benefit law, BIO Chairman Pops says. Group will work to ensure that FDA initiatives reducing drug development times continue after McClellan departs.
You may also be interested in...
President Bush nominates FDA Commissioner McClellan to head Centers for Medicare & Medicaid Services Feb. 20. McClellan's closest advisors will remain at FDA, suggesting era of greater cooperation between the two agencies could result.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.